<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
<LINK rel="stylesheet" type="text/css" href="be.css">
<META NAME="contextstring" CONTENT="Diureticsreducedcardiovasculardiseaseeventsindiabeticandnondiabeticpatients">
<META NAME="keywords" CONTENT="ACE inhibitors;Acute MI;Acute myocardial infarction;Adrenergic beta-antagonists;Adult-onset diabetes mellitus;AMI - acute myocardial infarction;Angiotensin I-converting enzyme inhibitors;Angiotensin-converting enzyme inhibition;Antihypertensive treatment;AODM;ARR;Arterial hypertension;ASHD;Atenolol;Atherosclerotic heart disease;B-adrenergic blockade;Benzothiadiazine diuretics;Beta blocker;Blood pressure, high;CAD;Cardiac death;Cardiac disease;Cardiac index;Cardiac mortality;Cardiovascular complications;Cardiovascular disease;Cardiovascular events;Cardiovascular mortality;Chlorthalidone;Chronic hypertension;Chronic hyponatremia;CI;Clinical depression;Clinical diabetes;Converting enzyme inhibitors;Coronary artery disease;Coronary artery stenosis;Coronary deaths;Coronary events;Coronary thrombosis;CVD;Depression;Depression screening;Depression, endogenous;Depressive disorder;Diabetes mellitus;Diabetes mellitus, type I;Diabetes mellitus, type II;Diabetic;Diabetic patients;Diastolic blood pressure;Diuretic thiazide;Diuretics;Drug reaction;Dyslipidemia;Dysthymia;Emotional depression;Essential hypertension;Fatal stroke;Heart attack;Heart disease;High blood pressure;HTN;Hygroton;Hyperglycemia;Hyperpiesis;Hypertension;Hypertensive patients;Hyperuricemia;Hypoglycemics;Hypokalemia;Hyponatremia;Hypopotassemia;IDDM;Idiopathic hypertension;Idiosyncratic drug reactions;Injurious effects;Insulin;Insulin dependent diabetes;Insulin resistance;Isolated systolic hypertension;K deficiency;Kininase II inhibitors;Major depression;Mason-type diabetes;Maturity-onset diabetes mellitus;MI - myocardial infarction;MODY;Myocardial infarction;NIDDM;NIDDY;NNT;Non-insulin dependent diabetes mellitus;Nondiabetic patients;Oral hypoglycemic agents;Organic heart disease;Postoperative MI;Potassium depletion;Primary hypertension;Q-wave myocardial infarction;Raupasil;Reserpine;Serpasil;Sexual dysfunction;Side effects;Sodium depletion;Spurious hypokalemia;Structural heart disease;Systemic primary arterial hypertension;Systolic hypertension;Tenormin;Thiazide;Treatment of high blood pressure;Type II diabetes;Uncontrolled hypertension;Undesirable effects">
<META NAME="groups" CONTENT="BE97:0270;ACPJC;Therapeutics">
<META HTTP-EQUIV="Content-Type" Content="text-html; charset=Windows-1252">
<title>2000 - Review: Isolated systolic hypertension increases mortality and morbidity in elderly persons and should be treated</title>
</HEAD>
<BODY BGCOLOR=#FFFFFF TEXT=#000000>
<P CLASS="BEsection">Therapeutics</p>
<P CLASS="AbsTitl"><a name="diureticsreducedcardiovasculardiseaseeventsindiabeticandnondiabeticpatients"></a><a href="be4f86er.htm"></a>Review: 
  Isolated systolic hypertension increases mortality and morbidity in elderly 
  persons and should be treated</p>
<P CLASS="ACPSource">ACP Journal Club. 2000 Sept-Oct;133:41.<BR>
</p>
<P CLASS="Citation">Staessen JA, Gasowski J, Wang JG, et al. <b>Risks of untreated 
  and treated isolated systolic hypertension in the elderly: meta-analysis of 
  outcome trials.</b> Lancet. 2000 Mar 11;355:865-72. </p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="AbsHd">Questions</p>
<P CLASS="AbsTxt">In elderly persons, what are the risks associated with isolated 
  systolic hypertension (<img src="../Assets/greaterthansign.gif" width="6" height="9"> 
  160 mm Hg with diastolic blood pressure [BP] &lt; 95 mm Hg), and what is the 
  magnitude of the benefit associated with treatment? </p>
<P CLASS="AbsHd">Data sources</p>
<P CLASS="AbsTxt">Studies were identified from 10 published overviews and 2 reports 
  from trialist collaborations.</p>
<P CLASS="AbsHd">Study selection</p>
<P CLASS="AbsTxt">Controlled trials were selected if elderly persons with isolated 
  systolic hypertension were enrolled. Trials were excluded if all the study participants 
  had comorbid conditions, such as stroke; if specialized care was compared with 
  routine antihypertensive agents; and if the study was a preliminary evaluation 
  for a larger study. </p>
<P CLASS="AbsHd">Data extraction</p>
<P CLASS="AbsTxt">Data were extracted on study quality, patient characteristics, 
  antihypertensive treatment, duration and length of follow-up, and outcomes (all-cause 
  and cardiovascular mortality, cardiovascular complications, all strokes, and 
  all coronary events). Strokes did not include transient ischemic attacks. Cardiovascular 
  complications included coronary artery disease (myocardial infarction and sudden 
  death), stroke, and vascular disorders. </p>
<P CLASS="AbsHd">Main results</p>
<P CLASS="AbsTxt">8 trials (15 693 patients) were included. Mean age range was 
  62 to 76 years, median follow-up was 3.8 years, prevalence of smoking at baseline 
  was 16%, and 31% of participants had <img src="../Assets/greaterthansign.gif" width="6" height="9">1 
  cardiovascular complication at baseline. All-cause mortality was positively 
  associated with systolic BP (P &lt; 0.001) and negatively associated with diastolic 
  BP (P = 0.05): With any given increase in systolic BP, a lower diastolic BP 
  increased the risk for death. For each 10-mm increase in systolic BP, an increase 
  was shown in all-cause mortality (hazard ratio [HR] 1.26, 95% CI 1.13 to 1.40), 
  cardiovascular death (HR 1.22, CI 1.06 to 1.40), cardiovascular events (HR 1.15, 
  CI 1.04 to 1.28), and stroke (HR 1.22, CI 1.04 to 1.40) but not coronary events 
  (HR 1.07, CI 0.91 to 1.26). For each 5-mm Hg increase in diastolic BP, a decrease 
  in all-cause mortality was found (HR 0.95, CI 0.89 to 1.00). </p>
<P CLASS="AbsTxt">With treatment, the mean reduction was 10.4 (range 6.9 to 18.2) 
  in systolic BP and 4.1 (range 2.3 to 8.3) mm Hg in diastolic BP. An improvement 
  in all outcomes was found when results for all trials were pooled (Table). Summary 
  analysis showed that all outcomes improved with treatment even across subgroups 
  based on sex, age, systolic BP, pulse pressure, previous cardiovascular complications, 
  and smoking status. </p>
<P CLASS="AbsHd">Main outcome measures</p>
<P CLASS="AbsTxt">Combined nonfatal and fatal stroke, nonfatal myocardial infarction (MI) or cardiac death, major coronary heart disease (CHD), and major CVD.</p>
<P CLASS="AbsHd">Conclusion</p>
<P CLASS="AbsTxt">Isolated systolic hypertension and wide pulse pressure in elderly 
  persons increase the risk for mortality and morbidity. Treatment reduces this 
  risk. </p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="Grant">Source of funding: Not stated.</p>
<P CLASS="Reprint">For correspondence: Dr. J.A. Staessen, Studie-co&ouml;rdinatiecentrum, 
  Laboratorium Hypertensie, Campus Gasthuisberg, Gebouw Onderwijs en Navorsing, 
  Herestraat 49, B-3000 Leuven, Belgium. FAX 32-16-347106. </p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="TablTitl">Treatment of isolated systolic hypertension in elderly persons*</p>
<table cellspacing=0 cellpadding=3 width="100%" border=0>
  <tbody> 
  <tr valign=top> 
    <th class=colhdl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Outcomes 
      at mean 3.8 y </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Odds 
      ratio reduction (95% CI) </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">NNT 
      (CI) </font></th>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All-cause 
      mortality </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">13% 
      (2 to 22) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">59 
      (55 to 64) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Cardiovascular 
      mortality </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">18% 
      (4 to 29) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">79 
      (72 to 89) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
      cardiovascular events </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26% 
      (17 to 34) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26 
      (25 to 27) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
      stroke events </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">30% 
      (18 to 41) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">48 
      (45 to 51) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">All 
      coronary events </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">23% 
      (10 to 34) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">64 
      (59 to 70) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  </tbody>
</table>
<P CLASS="TablFootn"><font class=textblack 
      face="arial, helvetica, sans-serif" size=2><font 
      class=pageboldgrn size=2>*Abbreviations defined in <a 
      href="../Assets/Glossary2.html" target="_blank">Glossary</a>. 
  1 trial was not a randomized controlled trial; reanalysis without this trial 
  did not alter outcomes significantly.</font></font></p>
<hr size=2 color=#3399CC>
<P CLASS="CmHd">Commentary</p>
<P CLASS="CmTxt">Clinicians, be comforted! This sophisticated meta-analysis by 
  Staessen and colleagues confirms what we already know: Systolic BP better predicts 
  cardiovascular events than does diastolic BP, and absolute 5-year benefits of 
  antihypertensive drug therapy are greater among persons with higher baseline 
  risks, such as men, older adults, and persons with known cardiovascular disease. 
  It also confirms several observational studies that show that wider pulse pressure—a 
  measure dependent on ventricular ejection, timing of blood pressure waves, and 
  arterial stiffness—is associated with higher baseline risks. </p>
<P CLASS="CmTxt">Should we now routinely use pulse pressure rather than systolic 
  and diastolic BP measurements alone? Not yet. First, for those who rely on risk 
  assessment to determine when benefits of treatment are likely to outweigh harms, 
  we need changes in current risk-assessment tools to incorporate pulse pressure. 
  Second, antihypertensive agents have multiple and heterogeneous effects, and 
  the pathophysiology of hypertension is complex; all agents are not equivalent 
  despite equivalent BP reduction (1). We do not yet know whether differences 
  in drug benefits are caused by differences in reducing pulse pressure. </p>
<P CLASS="CmTxt">Active research to improve evidence-based care of patients with 
  hypertension is alive and well. The results of these studies are still subject 
  to change. What will the bottom line be? Clinicians, stand by! </p>
<P CLASS="CmAuth1">Ronald T. Ackermann, MD<br>
  Cynthia D. Mulrow, MD <BR>
  Audie L. Murphy Memorial Veterans Hospital<BR>
  San Antonio, Texas, USA</p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="CmRefHd">Reference</p>
<META NAME="Ref1">
<P CLASS="CmRef">1. <b>ALLHAT Collaborative Research Group</b>. Major cardiovascular 
  events in hypertensive patients randomized to doxazosin vs chlorthalidone: the 
  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
  (ALLHAT). JAMA. 2000;283:1967-75.</p>
<P CLASS="CmRef"><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000 size=2><font 
      class=pageboldgrn color=#009982 size=2><font 
      class=copyrightblue face="arial, sans-serif" color=#3399cc 
      size=1>Copyright &copy;2001 American College of Physicians – American Society 
  of Internal Medicine</font> </font></font></p>
</BODY>
</HTML>
